VRDN: Viridian Therapeutics Company Short-Term Debt

Symbol and logo of brand Viridian Therapeutics, Inc. (VRDN)

This chart illustrates that the market value of Viridian Therapeutics (VRDN) is 0.00. Viridian Therapeutics minimizes risks by developing a series of monoclonal antibodies for eye and thyroid therapies. Business success depends on regulatory approval and capital support. Currently, the strategy relies on internal R&D without engaging external partners or pursuing mergers.

VRDN (Viridian Therapeutics Inc) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Viridian Corp (VRDN)

- current quotes and average value forecast:
Price Chart Viridian Therapeutics, Inc.|VRDN - Fair Value Consensus
- market capitalization information:
Market Value Viridian Therapeutics, Inc.|VRDN - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Viridian Therapeutics|VRDN - Book Capitalization|Market Cap to Net Assets Ratio viridiantherapeutics.com|VRDN - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Viridian Therapeutics|VRDN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Viridian Therapeutics|VRDN - Company Cumulative Debt|Debts to Book Capitalization Viridian Therapeutics, Inc.|VRDN - Long-Term Debt|Company Short-Term Debt Viridian Therapeutics|Quick Liquidity Indicator viridiantherapeutics.com
- net income and valuation multiples indicators:
VRDN - Company Net Income
Basic company analysis:Viridian Therapeutics, Inc. (VRDN)
Manufactured products of viridiantherapeutics.com

Viridian Therapeutics (VRDN) leverages AI to automate the synthesis of ophthalmic drugs, although clinical trials require significant expenditures. Analyzing the short-term debt structure, an investor sees obligations maturing within one year. This metric aggregates current loans, excluding time lags. Debt reduction strengthens the balance sheet but may signal a restriction on bank credit limits. This determines the asset's liquidity.

Main competitors

ALC - Company Short-Term Debt|Company Short-Term Loans and Borrowings BLCO (Bausch & Lomb)|Glaukos Corp. (GKOS) - Company Short-Term Debt|Company Current Liabilities Apellis Corp|BLTE (Belite Bio Inc) - Company Short-Term Debts|Company Short-Term Debts ocutx.com|Company Current Liabilities HROW (Harrow)|LENZ (LENZ Therapeutics Inc) - Company Short-Term Loans and Borrowings|Company Short-Term Debts OCS (oculis.com)|EyePoint Corp (EYPT) - Short-Term Debt|KOD: Company Current Liabilities|Short-Term Debt Aldeyra Therapeutics|KALA: Company Short-Term Debts|Short-Term Debt Opus Genetics (IRD)|Company Short-Term Debt OKYO Pharma Ltd|Adverum (ADVM) - Short-Term Debt Volume|Company Current Liabilities OTLK (Outlook Therapeutics)|Company Short-Term Debt CLSD (clearsidebio.com)|Company Short-Term Debts NBY (NovaBay Pharmaceuticals, Inc.)|Short-Term Debt Volume Kiora Pharmaceuticals Inc. (KPRX)|ALIM - Company Short-Term Debt|Company Short-Term Loans and Borrowings EYEN (Eyenovia, Inc.)|GHSI: Company Short-Term Debts|OCUP - Short-Term Debt Volume|OPT (Opthea) - Company Short-Term Debts